Brief: NewAmsterdam Pharma Announces Positive Topline Results From Phase 2B Obicetrapib Trial In Japanese Patients

NewAmsterdam Pharma

05/06/2023 12:44

June 5 (Reuters) - NewAmsterdam Pharma Company NV
 NAMS.O :
    * NEWAMSTERDAM PHARMA ANNOUNCES POSITIVE TOPLINE RESULTS
FROM
PHASE 2B DOSE-FINDING TRIAL EVALUATING OBICETRAPIB IN JAPANESE
PATIENTS
    * NEWAMSTERDAM PHARMA-ACHIEVED PRIMARY ENDPOINT WITH
STATISTICALLY
SIGNIFICANT 45.8% MEDIAN REDUCTION IN LDL-C IN PATIENTS TREATED
WITH 10MG OBICETRAPIB
    * NEWAMSTERDAM PHARMA COMPANY NV - FAVORABLE SAFETY AND
TOLERABILITY OBSERVED IN STUDY
    * NEWAMSTERDAM PHARMA - PLAN TO LEVERAGE DATA FROM ONGOING
PHASE 3
BROOKLYN, BROADWAY AND PREVAIL TRIALS TO SUPPORT POTENTIAL
APPROVAL IN JAPAN

Source text for Eikon:  ID:nGNX723hPm 
Further company coverage:  NAMS.O 

 ((Reuters.Briefs@thomsonreuters.com))